Survey
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify April 2024
Ticker(s): RVNC, ABBV, EOLS, Galderma, Merz AestheticsThe survey results includes 20 Dermatologists/Cosmetic Plastic Surgeons.
What is the number of patients you treat with frown line injections on average each month?
Are you familiar with Daxxify (DaxibotulinumtoxinA-lanm) and data to date?
What is the percentage breakdown of frown line injection brands you currently use?
- Daxxify
- Botox
- Dysport
- Jeuveau
- Xeomin
- Other
What is the percentage breakdown of frown line injection brands you expect to use in 1 year?
- Daxxify
- Botox
- Dysport
- Jeuveau
- Xeomin
- Other
Which injection do you prefer to use for the treatment?
- Daxxify
- Botox
- Dysport
- Jeuveau
- Xeomin
- Other, please specify
Please elaborate on your preference
How many of your patients currently use Daxxify?
How many patients do you expect to start Daxxify in the next 30 days?
How many patients have discontinued Daxxify in the last 30 days?
Do you expect your usage of Daxxify to increase moving forward?
Why or why not?
In your experience, what is the average duration (in terms of weeks) you’ve observed in the following injections:
- Daxxify
- Botox
How would you rate Daxxify on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Cost
How would you rate Botox on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Cost
How would you describe patient adoption and satisfaction with the Daxxify injection?
What features being added to future generations of injection treatments would have you consider switching brands or significantly shifting share?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
